NCT04198922View on ClinicalTrials.gov

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2027

Conditions
Recurrent Moderate-Severe Chronic Graft Versus Host DiseaseHematopoietic and Lymphoid Cell Neoplasm
Interventions
DRUG

Acalabrutinib

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (6)

14203

Roswell Park Comprehensive Cancer Center, Buffalo

33612

Moffitt Cancer Center, Tampa

37212

Vanderbilt University Medical Center, Nashville

43210

The Ohio State University Wexner Medical Center, Columbus

77030

The University of Texas MD Anderson Cancer Center, Houston

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER